MedMira Inc.
155 Chain Lake Drive
Halifax
Nova Scotia
B3S 1B3
Canada
Tel: 902-450-1588
Fax: 902-450-1580
Website: http://www.medmira.com/
Email: ir@medmira.com
129 articles about MedMira Inc.
-
MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System
3/13/2024
MedMira Inc. announces the receipt of a Canadian patent patent for its new innovative and quantitative test system.
-
Corporate Update on Clinical Evaluation of MedMira’s Products
2/1/2024
MedMira Inc. is pleased to provide an update on the ongoing review process by Health Canada.
-
MedMira Reports First Quarter Results FY2024
12/29/2023
MedMira Inc., reported on its financial results for the quarter ended October 31, 2023.
-
U.S. FDA Approves MedMira's Advanced Reveal G4 Rapid HIV-1/2 Antibody Test
12/13/2023
MedMira Inc. proudly announces the successful attainment of 510 clearance for the HIV-2 claim on the Reveal® G4 Rapid HIV-1/2 antibody test in the United States.
-
MedMira Reports FY2023 Fourth Quarter and Year End Financial Results
11/28/2023
MedMira Inc., reported on its financial results for the financial year ended July 31, 2023.
-
Update on MedMira’s Regulatory Path in Canada and the USA
9/27/2023
MedMira Inc. provides an update on its progress to achieve regulatory approval in Canada and the USA for its infectious disease rapid tests.
-
Progress Update on Securities
8/30/2023
MedMira Inc. has completed, with its Transfer Agent, the process and has received confirmation by the TSX.v as follows:.
-
MedMira Reports Third Quarter Results FY2023
6/29/2023
MedMira Inc., reported on its financial results for the quarter ended April 30, 2023.
-
MedMira Reports Second Quarter Results FY2023
4/3/2023
MedMira Inc., reported on its financial results for the quarter ended January 31, 2023.
-
Update on MedMira’s Reveal TP (Syphilis) Clinical Trials in Canada
3/14/2023
MedMira Inc. provides an update on its progress to achieve regulatory approval in Canada for its Reveal® TP antibody test.
-
MedMira Enters into Partnership with Maternova for USA and Latin America
2/20/2023
MedMira Inc. announces the singing of a multinational distribution agreement with Maternova, Inc., Rhode Island, USA.
-
MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test
1/11/2023
Today, MedMira Inc. (MedMira) (TSXV:MIR) announces the receipt of the CE mark for its VYRA CoV2Flu Antigen Test.
-
Point-of-Care Diagnostic for Trichomonas Vaginalis Based on MedMira's RVF Technology(R)
1/3/2023
MedMira Inc. announces the publication of Point-of-Care Diagnostic for Trichomonas vaginalis, the Most Prevalent, Non-Viral Sexually Transmitted Infection -, in the special edition of Pathogens by MDPI, a Swiss based medical journal.
-
MedMira Reports First Quarter Results FY2023
12/30/2022
MedMira Inc., reported on its financial results for the quarter ended October 31, 2022.
-
MedMira Introduces VYRA TriDemic
12/29/2022
MedMira Inc. presents its latest addition to the VYRATM product line, the VYRATM TriDemic Antigen Rapid Test for the simultaneous detection of SARS-CoV-2, Flu A, Flu B and Respiratory Syncytial Virus.
-
MedMira Receives CE Mark for Its VYRA(TM) COVID-19 Antigen Test
10/14/2022
MedMira Inc. announces the receipt of the CE mark for its VYRA™ COVID-19 Antigen Test, the fastest SARS-CoV-2 Antigen test available.
-
MedMira Strengthens and Expands Board
7/14/2022
Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the appointment of Ms. Pascale Nini to the Board of Directors. In addition, Mr. Thomas Bergmann was appointed as the Company’s independent Chairman.
-
MedMira Reports Third Quarter Results FY2022
6/29/2022
MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended April 30, 2022.
-
MedMira Receives Patent for its Unique Quantitative Diagnostic System
6/6/2022
Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of a U.S. patent (number 11,353,450) for their new innovative and quantitative test system.
-
MedMira provides an update on the new In Vitro Diagnostic Medical Devices Regulation (IVDR) in the European Market
5/27/2022
Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its regulatory progress in Europe and any market accepting the CE mark.